A REVIEW ON POLOXAMER AND HYDROXY PROPYL METHYL CELLULOSE COMBINATION AS THERMORESPONSIVE POLYMERS IN NOVEL OPHTHALMIC IN SITU GEL FORMULATION AND THEIR CHARACTERIZATION
Poor bioavailability is one of the most significant problems in the delivery of the ocular drug system. Ophthalmic ointments, solutions and suspensions are the most frequently used dosage forms to treat ocular disease, and their effectiveness as a drug are compromised by several limitations that lead to poor ocular bioavailability. In situ gel is one of the most promising strategy and solutions to improve the ocular bioavailability of drugs. The purpose of this review is to discuss the formulation and characterization of in situ gel. This review is written based on the data or information obtained by using several search engines and several scientific journals, focused on Poloxamer 407 and Hydroxy Propyl Methyl Cellulose (HPMC) bases combination.
Active ingredients to treat ocular disease such as Ciprofloxacin, Fluconazole and Ofloxacin can be formulated with the combination of Poloxamer 407 as polymer gelling agent and HPMC as viscosity enhancer to produce good quality in situ gel dosage forms. The in situ gel dosage forms can be a promising alternate solution for the ophthalmic delivery system.
2. Wu Y, Liu Y, Li X, Kebebe D, Zhang B, Ren J, et al.Research progress of in-situ gelling ophthalmic drug delivery system. Asian J Pharm Sci 2019;14:1-15.
3. Fathalla MA, Vangala ZA, Longman M, Khaled KA, Hussein AK, ElGarhy OH,Alany RG. Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: design, characterisation, toxicity and transcorneal permeation studies. Eur J Pharm Biopharm 2017;114:119-34.
4. Preethi GB, Narendra E. Formulation and evaluation of in situ mucoadhesive ophthalmic hydrogel for sustained delivery of pefloxacin mesylate. Int J Pharm Pharm Sci 2015;7:345-50.
5. Anuja TK, Rahul LJ, Pradnya BS, Satwashila SK. Design and evaluation of modified chitosan based in situ gel for ocular drug delivery. Int J Pharm Pharm Sci 2017;9:87-91.
6. Agarwal K, Mehta N, Namdev A, Gupta A. In-situ gel formation for ocular drug delivery system an overview. Asian J Biomed Pharm Sci 2011;1:1-7.
7. Lou J, Hu W, Tian R, Zhang H, Jia Y, Zhang J, et al. Optimization and evaluation of a thermoresponsive ophthalmic in situ gel containing curcumin-loaded albumin nanoparticles. Int J Nanomed 2014;9:2517-25.
8. Rajoria G, Gupta A. In-situ gelling system: a novel approach for ocular drug delivery. Am J PharmTech Res 2012;2:24-53.
9. Kotreka UK, Davis VL, Adeyeye MC. Development of topical ophthalmic In situ gel forming estradiol delivery system intended for the prevention of age-related cataracts. Plos One2017;12:1-19.
10. Lin HR, Sung KC. Carbopol/Pluronic phase change solutions for ophthalmic drug delivery. J Controlled Release 2000;69:379-88.
11. Parekh HB, Rishad J, Jivani NP, Patel LD, Makwana A, Sameja K. Novel in situ polymeric drug delivery system: a review. J Drug Delivery Ther 2012;2:136-45.
12. Nirmal HB, Bakliwal SR, Pawar SP. In situ gel: new trends in controlled and sustained drug delivery system. Int J Pharm Tech Res 2010;2:1398-408.
13. Nerkar TS, Gujarathi NA, Bhushan R, Bakliwal SR, Pawar SP. In situ gel: novel approach in sustained and controlled drug delivery system. Pharma Sci Monitor 2013;4:1-18.
14. Chand P, Pratibha, Gnnarajan G, Kothiyal. In situ gel: a review. Indian J Pharm Biol Res 2016;4:11-9.
15. Saini R, Saini S, Singh G, Banerjee A. In situ gels-a new trends in ophthalmic drug delivery systems. Int J Pharm Sci Res2015;6:886-90.
16. Laddha UD, Mahajan HS. An insight to ocular in situ gelling systems. Int J Adv Pharm 2017;6:31-40.
17. El Laithy H, Nesseem D, Shoukry M. Evaluation of two in situ gelling systems for ocular delivery of Moxifloxacin: in vitro and in vivo studies. J Chem Pharm Res 2011;3:66-79.
18. Rathore KS. In situ gelling ophthalmic drug delivery system: an overview. Int J Pharm Sci Res 2010;2:30-4.
19. Cao Y, Zhang C, Shen W. Poly (N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. J Controlled Release 2007;120:186-94.
20. Kute PR, Gondkar SB, Saudagar RB. Ophthalmic in-situ gel: an overview. World J Pharm Pharm Sci 2015;4:549-68.
21. Israr S, Nesalin J, Mani TT. A novel approach of ophthalmic drug delivery: in situ gel. J Pharm Res 2015;4:121-4.
22. Gowda DV, Tanuja D, Khan MS, Desai J, Shivakumar HG. Formulation and evaluation of in-situ gel of diltiazem hydrochloride for nasal delivery. Pharm Lett2011;3:371-81.
23. Makwana SB, Patel VA, Parmar SJ. Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride. Results Pharm Sci 2016;6:1-6.
24. Aishwarya JJ, Sheetal BG, Ravindra BS. A review on nasal drug delivery system. World J Pharm Pharm Sci 2014;3:231-54.
25. Prajapati N,Goyal A. A review: thermoreversible mucoadhesive in-situ gel. Int J Innovative Drug Discovery 2013;3:67-84.
26. Pawar P, Kashyap H, Malhotra S, Rakesh S. Hp-?-CD-voriconazole in situ gelling system for ocular drug delivery: in vitro, stability, and antifungal activities assessment. Biomed Research International 2013:1-9. DOI:10.1155/2013/341218
27. Choi HG, Jung JH, Ryu JM, Yoon SJ, Oh SYK, Kim CK. Development of in situ-gelling and mucoadhesive acetaminophen liquid suppository. Int J Pharm 1998;165:33-44.
28. Geethalakshmi A, Karki R, Jha SK, Venkatesh DP, Nikunj B. Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system. Curr Drug Delivery 2012;9:197-204.
29. Wee S, Gombotz WR. Protein release from alginate matrices. Adv Drug Delivery Rev 1998;31:267-85.
30. Champalal KD, Sushilkumar P. Current status of ophthalmic in situ forming hydrogel. Int J Pharm Bio Sci 2012;3:372-88.
31. Nanjawade. In situ forming hydrogels for sustained ophthalmic drug delivery. J Controlled Release 2007;122:119-34.
32. Nagaich U, Jain N, Kumar D, Gulati N. Controlled ocular drug delivery of ofloxacin using temperature modulated in situ gelling system. J Sci Soc2013;40:90-4.
33. Ali Khatera NA, Soliman OA, Mohamed EA. In situ gelling ophthalmic formulations for sustained release and enhanced ocular delivery of fluconazole.J Pharm Biol Sci 2016;11:43-51.
34. Kumar D, Jain N, Gulati N, Nagaich U. Nanoparticles laden in situ gelling system for ocular drug targeting. J Adv Pharm Technol Res 2013;4:9-17.
35. Jethava JK, Jethava GK. Design, formulation, and evaluation of novel sustain releasebioadhesive in-situ gelling ocular inserts of ketorolac tromethamine. Int J Pharm Investig 2014;4:226-32.
36. Kurniawansyah IS, Rusdiana T, Wahab HA, Subarnas A. In situ ophthalmic gel with ion activated system. Int J Appl Pharm 2019;11:15-8.
37. Jain D, Kumar V, Singh S, Mullertz A, Bar Shalom D. Newer trends in in situ gelling systems for controlled ocular drug delivery. J Anal Pharm Res 2016;2:22.
38. Deka M, Ahmed AB, Chakraborty J. Development, evaluation and characteristics of ophthalmic in situ gel system: a review.Int J Curr Pharm Res 2019;11:47-53.
39. Majeed A, Khan NA. Ocular in situ gel: an overview. J Drug Delivery Ther 2019;9:337-47.
40. Madan JR, Adokar BR, Dua K. Development and evaluation of in situ gel of pregabalin. Int J Pharm Investig 2015;5:226-33.
41. Patel N, Thakkar V, Metalia V, Baldaniya L, Gandhi T, Gohel M. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept. Drug Dev Ind Pharm 2016;42:1406-23.
42. Kurniawansyah IS, Sopyan I, Wardhana YW, Gunasekaran M. Formulation and evaluation of chlorampenicol hydrogel opthalmic preparation. J Young Pharm 2018;10:73-8.
43. Kadam S, Kondawar M, Kamble K. Formulation and evaluation of in situ gellingsystem of ketrolac tromethamine for ophthalmic drug delivery. Int J Pharm Ther 2010;1:64-71.
44. Shashank NN, Srinivasa U. Design and evaluation of ion activated in situ ophthalmic gel of moxifloxacin hydrochloride and ketorolac tromethamine combination using carboxy methylated tamarind kernel powder. Saudi J Med Pharm Sci 2017;3:1-8.
45. Verma L, Sakir M, Singh N, Gilhotra MN, Mehan S. Development of phase change solutions for ophthalmic drug delivery based on ion activated and pH induced polymers. Int J Pharma Professional’s Res 2010;1:127-34.
46. Sundari PJP, Maddela R, Srinivas P. Formulation and evaluation of thermosenstive ocular in situ gels for sustained release of balofloxacin. World J Pharm Pharm Sci 2015;4:835-45.
47. Barse RK, Tagalpallewar AA, Kokare CR, Sharma JP, Sharma PK. Formulation and ex vivo-in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 32 factorial design. Drug Dev Ind Pharm 2017;44:800-7.
48. Sun J, Zhou Z. A novel ocular delivery of brinzolamide based on gellan gum: in vitro and in vivo evaluation. Drug Des Dev Ther 2018;12:383–9.
49. Kashikar VS, Gonjari ID. In situ gelling systems of ofloxacin: Comparative performance of in vivo precorneal drainage and pharmacokinetic study. Asian J Pharm 2013;7:15-20.
50. Balasubramaniam J, Kant S, Pandit JK.In vitro and in vivo evaluation of the Gelrite® gellan gum-based ocular delivery system for indomethacin. Acta Pharm 2003;53:251–61.
This work is licensed under a Creative Commons Attribution 4.0 International License.